Full Breakdown
Nationwide Recall of ByHeart Baby Formula Linked to Infant Botulism Outbreak
11/11/2025, 6:20:13 AM
Overview of the Recall
ByHeart, a producer of organic baby formula, has initiated a nationwide recall of its Whole Nutrition Infant Formula following a multi-state outbreak of infant botulism. The U.S. Food and Drug Administration (FDA) reported that 13 infants across 10 states have been hospitalized after consuming the formula, with no fatalities recorded as of November 10, 2025. The recalled products are identified by lot numbers 206VABP/251261P2 and 206VABP/251131P2, both with a "use by" date of December 1, 2026.
States Affected
The outbreak has been traced to cases in the following states: Arizona, California, Illinois, Minnesota, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas, and Washington. The California Department of Public Health first alerted the CDC to an increase in infant botulism cases linked to ByHeart formula, prompting further investigation.
Understanding Infant Botulism
Infant botulism is caused by the ingestion of spores from the bacterium Clostridium botulinum, which can produce toxins in an infant's intestines. Symptoms typically include constipation, poor feeding, loss of head control, and difficulty swallowing. If untreated, it can lead to severe complications, including paralysis and respiratory failure. The only treatment available is BabyBIG, an FDA-approved medication that helps mitigate the effects of the toxin.
Company Response and Testing
ByHeart has stated that preliminary tests indicated the presence of the bacteria in the formula, although they maintain that further testing is necessary to establish a direct link between their product and the illnesses. The company has engaged a third-party laboratory to conduct independent tests on the recalled batches. ByHeart emphasizes its commitment to safety, stating, "ByHeart is taking the proactive step to remove any potential risk from the market."
Criticism and Regulatory Oversight
Concerns have been raised regarding ByHeart's manufacturing practices. A January 2024 FDA inspection of ByHeart's Pennsylvania facility revealed multiple citations for unsanitary conditions. Critics, including Brian Ronholm from Consumer Reports, have expressed alarm over the company's failure to adequately address these issues. The FDA is currently reviewing comments from industry experts and the public to determine future regulatory actions.
Official Statements
The FDA has urged consumers to stop using the recalled formula immediately and to dispose of it properly. Parents are advised to monitor their infants for symptoms of botulism and seek medical attention if any signs appear. The CDC has confirmed that the recall is not expected to cause a nationwide formula shortage, as ByHeart accounts for less than 1% of the U.S. infant formula market.
Verbatim Quotes
- “Consumers in possession of this product should stop using it immediately,” — California Department of Public Health
- “ByHeart is taking the proactive step to remove any potential risk from the market and ensure the highest level of safety for infants,” — ByHeart Statement
- “It’s very troubling that ByHeart appears to not have adequately addressed the FDA’s concerns over the serious problem involving unsanitary and contamination risk conditions at their plant,” — Brian Ronholm, Head of Food Policy for Consumer Reports
What's Next
The FDA and state health officials are continuing their investigation into the outbreak, with results from ongoing testing expected in the coming weeks. Parents are encouraged to report any illnesses related to the consumption of ByHeart formula to their local health departments.
